AUSTIN, Texas, June 21, 2016 /PRNewswire/ -- Lumos Pharma, Inc. has further expanded its management team with the appointment of Carol A. Dutch as Senior Director, Patient Engagement. Ms. Dutch will create and lead global patient engagement projects to support the clinical development and pre-commercial phases of Lumos' rare and orphan disease pipeline projects.
Over the course of her 25-year career, Ms. Dutch has led successful global launches of ultra-rare products and developed innovative awareness programs, partnering with professional societies and patient advocacy organizations. Prior to joining Lumos, Dutch worked with Recordati Rare Diseases, Inc. in marketing and advocacy roles. She is actively involved with many disease patient organizations (NUCDF, APF) as well as umbrella groups such as Global Genes, the National Organization of Rare Disorders (NORD) and Rare Disease Legislative Advocates (RDLA).
"Disease awareness and patient advocacy relationships are so important in the rare disease space. Carol's robust global experience in these areas will help guide us during this pivotal time as Lumos starts clinical trials," said Rick Hawkins, Lumos Pharma Founder and CEO.
"We are so excited to be working with Carol. Her unique insight will assist in driving patient identification projects aimed to help our kids get accurate and swift diagnoses,"said Kim Tuminello, president of the Association Creatine Disorders (ACD).
Ms. Dutch holds a Masters in International Economic Management (MIEM/MBA) from the SDA Bocconi University, Milan, Italy and a B.S. from the University of Southern California (USC) in Business Administration.
"I am truly excited to be part of the dynamic leadership team and organization whose mission is so close to my heart," noted Ms. Dutch. "I am looking forward to working with groups that are critical to disease identification and treatment so that Lumos may deliver unique medicines to patients with rare diseases around the world."
About Lumos Pharma
Founded in 2011, Lumos Pharma is a clinical stage biotechnology company focused on bringing novel therapies to patients with severe, rare, and genetic diseases, whose medical needs are unmet. Lumos Pharma is led by an experienced management team with longstanding experience in the rare disease space. It's lead compound, LUM-001, is being developed to treat Creatine Transporter Deficiency, a relatively new and rare disorder, that results in intellectual disability and development delay in boys.
Contact: MP Mueller, 512-775-9227, email@example.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/lumos-pharma-appoints-carol-a-dutch-as-senior-director-patient-engagement-300287730.html
SOURCE Lumos Pharma